Company Analysis
Sign in

Rein Therapeutics, Inc. (RNTX)

Nasdaq: RNTX · Pharmaceutical Preparations · Austin, TX · filing with the SEC since 2007
Full chart Alerts Compare
Grade3.0
◀ Past 3.7● Present 3.3▶ Future 2.3
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

48 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Rein Therapeutics, Inc.’s names, not what it holds today.

Patents granted
48
48 utility, 1976 to Dec 31, 2025
Granted in 2025
3
in the last year the record reads
Applications published
93
3 of them in 2025
Names they are printed under
5
a former name, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
Aileron Therapeutics, Inc. a former name
US, as the owner printed on each patent
45 granted
22 published
Aileron Therapeutics, Inc. a former name
named as the applicant on its applications, in US
0 granted
64 published
Rein Therapeutics, Inc. its own name
US, as the owner printed on each patent
3 granted
2 published
Aileron Therapeutics, Inc., a Delaware Corporation a former name
US, as the owner printed on each patent
0 granted
4 published
Rein Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,497,431Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosisPharmaceuticalsRein Therapeutics, Inc.
Apr 22, 202512,280,089Dry powder formulation of caveolin-1 peptides and methods of use thereofPharmaceuticalsRein Therapeutics, Inc.
Apr 22, 202512,280,088Dry powder formulation of caveolin-1 peptides and methods of use thereofPharmaceuticalsRein Therapeutics, Inc.
Aug 17, 202111,091,522Peptidomimetic macrocycles and uses thereofPharmaceuticalsAileron Therapeutics, Inc.
May 18, 202111,008,366Peptidomimetic macrocyclesPharmaceuticalsAileron Therapeutics, Inc.
Apr 6, 202110,967,042Peptidomimetic macrocyclesPharmaceuticalsAileron Therapeutics, Inc.
Feb 2, 202110,905,739Peptidomimetic macrocycles and formulations thereofPharmaceuticalsAileron Therapeutics, Inc.
Jul 7, 202010,703,780Peptidomimetic macrocyclesPharmaceuticalsAileron Therapeutics, Inc.
Jun 2, 202010,669,230Disubstituted amino acids and methods of preparation and use thereofOrganic fine chemistryAileron Therapeutics, Inc.
Nov 12, 201910,471,120Peptidomimetic macrocycles and uses thereofPharmaceuticalsAileron Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 2, 20252025/0302910DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOFPharmaceuticalsRein Therapeutics, Inc.
Aug 28, 20252025/0268977COMPOSITIONS AND METHODS FOR PROTECTING TYPE 2 ALVEOLAR EPITHELIAL CELLS (AEC2)PharmaceuticalsRein Therapeutics, Inc.
Aug 21, 20252025/0262273MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF CHRONIC KIDNEY DISEASEPharmaceuticalsRein Therapeutics, Inc.
Apr 18, 20242024/0124518METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONSPharmaceuticalsAileron Therapeutics, Inc.
Apr 27, 20232023/0127248PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOFPharmaceuticalsAileron Therapeutics, Inc.
Apr 20, 20232023/0119612PEPTIDOMIMETIC MACROCYCLESPharmaceuticalsAileron Therapeutics, Inc.
Apr 6, 20232023/0106577PEPTIDOMIMETIC MACROCYCLES AND USES THEREOFPharmaceuticalsAileron Therapeutics, Inc.
Feb 2, 20232023/0037284COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLESPharmaceuticalsAileron Therapeutics, Inc.
Jan 20, 20222022/0017569METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONSPharmaceuticalsAileron Therapeutics, Inc.
Jan 6, 20222022/0000968PEPTIDOMIMETIC MACROCYCLESPharmaceuticalsAileron Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RNTX · research, not advice